The information contained in this website is for general information purposes only. The information is provided by IXA and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of IXA . We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, IXA takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
Amsterdam UMC spin-off PacingCure is the winner of the Venture Challenge at the online edition of the Dutch Life Science Conference on the 26th of November. PacingCure develops precision gene therapies for common cardiac arrhythmias and cardiomyopathies, aiming to restore the natural pacing of the heart. The company is founded on combined research from the […]
NewsVU startup Sports-f(x) is uitgeroepen tot winnaar van de 12e Dutch Sports Innovation Award 2020. Oprichter Nilas van Woersem ontving de prijs uit handen van jurylid Jan Hoefnagels voor de NextRound Boxing Bag, een slimme bokszak die direct feedback geeft. De Dutch Sports Innovation Award is de stimuleringsprijs voor een innovatief en kansrijk product of […]
NewsIn their quest of creating safe and effective immunotherapy cancer treatments, VU spinoff LUMICKS and Amsterdam UMC spinoff LAVA Therapeutics joined forces. The partnership aims to evaluate the efficacy of various tumor-specific γδ T-cell engagers based on the resulting binding strengths (cell avidity) between T cells and tumors, measured with LUMICKS newly installed z-Movi® Cell […]
News